Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

7976 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-25

Study Completion Date

2032-09-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The "simple" analysis of the exome can determine somatic and constitutional mutations. The major challenge lies in the translation of sequencing data into clinically relevant information allowing the clinician to guide his decision-making A "complex" analysis of the exome would provide access to structural DNA data, concerning mutational signatures, tumor mutational load, analysis of large deletions, loss of heterozygosity as well as amplification of certain genes which may have an impact on the management of patients.

No data available to date makes it possible to assess the clinical interest of the availability of its additional information resulting from a "complex" analysis compared to a "simple" analysis. The objective of the EXOMA2 study is to assess the proportion of patients for whom the proposed therapy is derived from its additional information (complex analysis) and would not have been possible with a classic exome analysis (simple analysis) .

We hereby formulate the hypothesis that a "complex" analysis on a population presenting a metastatic or locally advanced disease treated early (from the 1st line of treatment) will make it possible to determine therapeutic indications which could not be discovered with a "simple" analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

What Benefit of a Full Analysis of Exome? Routine Care Study in Patients With Solid Tumors

NCT02840604

Carcinoma

COMPLETED

EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

NCT04141462

Cancer Genetic Predisposition

RECRUITING NA

Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.

NCT06550687

All Types of Metastatic Solid Malignancy 1st-line Treatment Exome Analysis +1 more

RECRUITING NA

Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.

NCT01079429

Monoclonal Gammopathy of Undetermined Significance Smoldering Myeloma

TERMINATED

Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation

NCT02664389

Breast Cancer Ovarian Cancer Colorectal Cancer +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.